Nutraferon DOREE Injection

Nutraferon DOREE is specifically indicated for Complicated Intra-Abdominal Infections (cIAI) and Complicated Urinary Tract Infections (cUTI), including acute pyelonephritis and concurrent bacteremia caused by susceptible bacteria.

No. Regulatory authorities strictly warn that Doripenem is NOT approved for the treatment of Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HAP/VAP), as clinical trials in ventilator-associated pneumonia demonstrated lower cure rates and a higher all-cause mortality risk compared to comparator regimens. Furthermore, Doripenem must NEVER be administered via inhalation (pneumonitis risk).

Carbapenems, including Doripenem, rapidly and drastically reduce blood concentrations of valproic acid / divalproex sodium (often by 60–90% within 24–48 hours), which can trigger loss of seizure control and breakthrough convulsions. Concurrent use is generally avoided or requires switching to an alternative anticonvulsant or antibiotic.

Because Doripenem is cleared mainly through the kidneys, impaired renal filtration causes the drug to accumulate in the bloodstream. Adjusting the dose according to creatinine clearance ensures safe, effective bacterial eradication.

Patients are monitored for headache, nausea, diarrhea (including Clostridioides difficile colitis), infusion-site phlebitis, rash, or hypersensitivity reactions (cross-allergy with penicillins/cephalosporins).